2023
Pharming Group issues statement regarding the events surrounding Silicon Valley Bank
Financial updatesPharming Group N.V. is aware that the Federal Deposit Insurance Corporation (“FDIC”) has been appointed receiver of Silicon Valley Bank (“SVB US”) and that the Bank of England, barring any intervening events, intends to put Silicon Valley Bank UK Limited (“SVB UK”) into insolvency.
Notice of Full Year 2022 financial results
Financial updatesPharming Group N.V. confirms it will announce its unaudited Full Year 2022 financial results for the year ended December 31, 2022, on Thursday, March 16, 2023.
2022
Pharming Group reports earnings for the first nine months of 2022
Financial updatesPharming Group N.V. presents its preliminary, unaudited financial report for the first nine months ended September 30, 2022.
Pharming Group Notice of Q3 Results
Financial updatesPharming Group N.V. confirms it will announce financial results for the nine months ended September 30, 2022 on Thursday, October 27, 2022.
Pharming Group reports financial results for the first half of 2022
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022.
Pharming Group Notice of H1 2022 Results
Financial updatesPharming confirms it will announce financial results for the six months ended 30 June 2022 on Thursday, August 4, 2022.
Pharming Group reports financial results for the first quarter of 2022
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the first quarter of the year ended 31 March 2022.
Pharming Group Notice of Q1 2022 Results
Financial updatesPharming confirms it will announce financial results for the first quarter of the year ended 31 March 2022 on Thursday, 12 May 2022.
Pharming announces change in its holding in BioConnection following a substantial investment by new investor
Financial updatesFollowing an agreed investment by European investment company Gimv, Pharming’s minority stake of 43.85% in BioConnection will reduce to 22.98%. As a result of this transaction, Pharming will receive one-off US$ 7.5 million (EUR 6.9 million) net cash proceeds.